AU9218398A - Human papilloma virus inhibition by anti-sense oligonucleotides - Google Patents

Human papilloma virus inhibition by anti-sense oligonucleotides Download PDF

Info

Publication number
AU9218398A
AU9218398A AU92183/98A AU9218398A AU9218398A AU 9218398 A AU9218398 A AU 9218398A AU 92183/98 A AU92183/98 A AU 92183/98A AU 9218398 A AU9218398 A AU 9218398A AU 9218398 A AU9218398 A AU 9218398A
Authority
AU
Australia
Prior art keywords
seq
antisense
analogs
hpv
bond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU92183/98A
Other languages
English (en)
Inventor
Luis Alvarez-Salas
Joseph Dipaolo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of AU9218398A publication Critical patent/AU9218398A/en
Priority to AU2002300401A priority Critical patent/AU2002300401C1/en
Priority to AU2002300399A priority patent/AU2002300399C1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
AU92183/98A 1997-09-05 1998-09-03 Human papilloma virus inhibition by anti-sense oligonucleotides Abandoned AU9218398A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002300401A AU2002300401C1 (en) 1997-09-05 2002-07-31 Human papilloma virus anti-sense oligonucleotides
AU2002300399A AU2002300399C1 (en) 1997-09-05 2002-07-31 Human papilloma virus inhibition by anti-sense oligonucleotides

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/929,140 US6084090A (en) 1997-09-05 1997-09-05 Human papilloma virus anti-sense oligonucleotides
US08929140 1997-09-05
PCT/US1998/018320 WO1999013071A1 (en) 1997-09-05 1998-09-03 Human papilloma virus inhibition by anti-sense oligonucleotides

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2002300399A Division AU2002300399C1 (en) 1997-09-05 2002-07-31 Human papilloma virus inhibition by anti-sense oligonucleotides
AU2002300401A Division AU2002300401C1 (en) 1997-09-05 2002-07-31 Human papilloma virus anti-sense oligonucleotides

Publications (1)

Publication Number Publication Date
AU9218398A true AU9218398A (en) 1999-03-29

Family

ID=25457385

Family Applications (1)

Application Number Title Priority Date Filing Date
AU92183/98A Abandoned AU9218398A (en) 1997-09-05 1998-09-03 Human papilloma virus inhibition by anti-sense oligonucleotides

Country Status (7)

Country Link
US (2) US6084090A (https=)
EP (2) EP1595954A1 (https=)
JP (1) JP2002509692A (https=)
KR (1) KR100604218B1 (https=)
AU (1) AU9218398A (https=)
CA (1) CA2302148A1 (https=)
WO (1) WO1999013071A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061804A1 (en) * 1999-04-14 2000-10-19 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
EP1353935A4 (en) * 2000-12-07 2005-02-23 Penn State Res Found SELECTION OF TARGET CATALYTIC NUCLEIC ACIDS ON INFECTIOUS AGENTS
DE10154831A1 (de) * 2001-11-08 2003-06-05 Deutsches Krebsforsch PNA-Konjugat oder PNA-Konjugat-Gemisch zur Therapie von mit HPV in Zusammenhang stehenden Erkrankungen
US7704965B2 (en) * 2002-06-26 2010-04-27 The Penn State Research Foundation Methods and materials for treating human papillomavirus infections
US20040248085A1 (en) * 2002-11-29 2004-12-09 Sang-Wha Lee General primers and process for detecting diverse genotypes of human papillomavirus by PCR
GB0500999D0 (en) * 2005-01-18 2005-02-23 Glaxosmithkline Biolog Sa Detection method and materials therefor
KR101197627B1 (ko) 2010-01-18 2012-11-07 (주)레퍼런스바이오랩 Ｈｐｖ 감염과 관련된 암의 치료용 조성물
KR102129852B1 (ko) * 2016-10-11 2020-07-24 주식회사 인코드젠 Rna 간섭 유도 핵산 및 이를 포함하는 hpv 감염 유발 암의 치료용 약학 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457189A (en) * 1989-12-04 1995-10-10 Isis Pharmaceuticals Antisense oligonucleotide inhibition of papillomavirus
AU687492B2 (en) * 1993-11-16 1998-02-26 Genta Incorporated Synthetic oligomers having phosphonate internucleosidyl linkages of undefined chirality mixed with non-phosphonate internucleosidyl linkages
US5683902A (en) * 1994-05-13 1997-11-04 Northern Illinois University Human papilloma virus inhibition by a hairpin ribozyme
US5580967A (en) * 1994-05-13 1996-12-03 The Scripps Research Institute Optimized catalytic DNA-cleaving ribozymes
US6509149B2 (en) * 1995-06-06 2003-01-21 Hybridon, Inc. HPV-specific oligonucleotides

Also Published As

Publication number Publication date
EP1009823A1 (en) 2000-06-21
WO1999013071A1 (en) 1999-03-18
EP1595954A1 (en) 2005-11-16
CA2302148A1 (en) 1999-03-18
US6084090A (en) 2000-07-04
JP2002509692A (ja) 2002-04-02
KR20010015573A (ko) 2001-02-26
KR100604218B1 (ko) 2006-07-25
US6277980B1 (en) 2001-08-21

Similar Documents

Publication Publication Date Title
CA2210353C (en) Stabilized external guide sequences
EP1035870B1 (en) Compositions and methods for treatment of hepatitis c virus-associated diseases
US6057153A (en) Stabilized external guide sequences
CA2162361C (en) Antisense oligonucleotides which combat aberrant splicing and methods of using the same
Giles et al. Detection of ribonuclease H-generated mRNA fragments in human leukemia cells following reversible membrane permeabilization in the presence of antisense oligodeoxynucleotides
US5563255A (en) Antisense oligonucleotide modulation of raf gene expression
US20040033978A1 (en) Compositions and methods for treatment of Hepatitis C virus-associated diseases
Brown-Driver et al. Inhibition of translation of hepatitis C virus RNA by 2′-modified antisense oligonucleotides
WO1996039502A1 (en) Oligonucleotides specific for hepatitis b virus
AU1832900A (en) Cancer cell vaccine
US6458940B2 (en) HPV-specific oligonucleotides
Alt et al. Comparative inhibitory potential of differently modified antisense oligodeoxynucleotides on hepatitis C virus translation
EP1595954A1 (en) Human papilloma virus inhibition by antisense oligonucleotides
US6090626A (en) Antisense oligonucleotide modulation of raf gene expression
CA2226457C (en) Oligonucleotides specific for human papilloma virus
AU2002300399B2 (en) Human papilloma virus inhibition by anti-sense oligonucleotides
Hatta et al. Inhibition of influenza virus RNA polymerase and nucleoprotein genes expression by unmodified, phosphorothioated, and liposomally encapsulated oligonucleotides
Márquez-Gutiérrez et al. Effect of combined antisense oligodeoxynucleotides directed against the human papillomavirus type 16 on cervical carcinoma cells
Kiely Recent advances in antisense technology
US20040049021A1 (en) Compositions and mehtods for treatment of Hepatitis C virus-associated diseases
US20030055240A1 (en) HPV specific oligonucleotides

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted